The changing competitive landscape in the global generics market: Threat or opportunity?

Journal of Generic Medicines

Volumn 3, Issue 4, 2006, Pages 269-279

  Karwal, Vijay ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CEFTRIAXONE; FENTANYL; FEXOFENADINE; GABAPENTIN; GENERIC DRUG; PAROXETINE;

ARTICLE; COMMERCIAL PHENOMENA; COMPETITION; DRUG COST; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; INDIA; PATENT; PROFIT;

EID: 33846831761     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4940129     Document Type: Article

References (6)

1. Wall Street Journal, European Edition, 27th July, 2005.
2. ABN AMRO research, based on 2004 product sales, pro-forma for announced acquisitions.
3. Market sizes as per Datamonitor 2004 Global Generics Report. Growth rates from Graham Lewis, IMS, presentation at IGPA Conference, Malta, June 2005.
4. Lewis, G. (2005) presentation at IGPA Conference, Malta, June.
5. ABN AMRO research
6. Gross, D., Schondelmeyer, S. and Raetzman, S. (2005) 'Trends in Manufacturing List Prices of Generic Prescription Drugs used by Older Americans', AARP Public Policy Institute, Washington, DC.